NUR 651 Exam 2 Questions
and Answers Latest Versions
2025 Graded A+.
Tiotropium bromide (Spiriva) is an inhaled anticholinergic: 1.Used for
the treatment of chronic obstructive pulmonary disease (COPD)
2.Used in the treatment of asthma 3. Combined with albuterol for
treatment of asthma exacerbations 4.Combined with fluticasone for
the treatment of persistent asthma
1.Used for the treatment of chronic obstructive pulmonary disease (COPD)
Christy has exercise-induced and mild persistent asthma and is
prescribed two puffs of albuterol 15 minutes before exercise and as
needed for wheezing. One puff per day of beclomethasone (QVAR) is
also prescribed. Teaching regarding her inhalers includes: 1. Use one
to two puffs of albuterol per day to prevent an attack with no more
than eight puffs per day 2. Beclomethasone needs to be used every
day to treat her asthma 3. Report any systemic side effects she is
experiencing, such as weight gain 4. Use the albuterol metered-dose
inhaler (MDI) immediately after her corticosteroid MDI to facilitate
bronchodilation
2. Beclomethasone needs to be used every day to treat her asthma
When prescribing montelukast (Singulair) for asthma, patients or
parents of patients should be instructed: 1.Montelukast twice a day is
started when there is an asthma exacerbation. 2.Patients may
experience weight gain on montelukast. 3.Aggression, anxiety,
depression, and/or suicidal thoughts may occur when taking
montelukast. 4.Lethargy and hypersomnia may occur when taking
montelukast.
3.Aggression, anxiety, depression, and/or suicidal thoughts may occur
when taking montelukast.
Montelukast (Singulair) may be prescribed for: 1. A 6-year-old child
with exercise-induced asthma 2. A 2-year-old child with moderate
,persistent asthma 3. An 18-month-old child with seasonal allergic
rhinitis 4. None of the above; montelukast is not approved for use in
children
2. A 2-year-old child with moderate persistent asthma
The known drug interactions with the inhaled corticosteroid
beclomethasone (QVAR) include: 1.Albuterol 2. MMR vaccine 3.Insulin
4. None of the above
4. None of the above
When educating patients who are starting on inhaled corticosteroids,
the provider should tell them that: 1. They need to get any live
vaccines before starting the medication. 2. Inhaled corticosteroids
need to be used daily during asthma exacerbations to be effective.
3. Patients should rinse their mouths out after using the inhaled
corticosteroid to prevent thrush. 4. They can triple the dose number
of inhalations of medication during colds to prevent needing systemic
steroids.
3. Patients should rinse their mouths out after using the inhaled
corticosteroid to prevent thrush.
Patients with allergic rhinitis may benefit from a prescription of: 1.
Fluticasone (Flonase) 2.Cetirizine (Zyrtec) 3. OTC cromolyn nasal
spray (Nasalcrom) 4.Any of the above
4.Any of the above
Howard is a 72-year-old male who occasionally takes
diphenhydramine for his seasonal allergies. Monitoring for this
patient taking diphenhydramine would include assessing for:
1.Urinary retention 2. Cardiac output 3. Peripheral edema 4.Skin rash
1.Urinary retention
First-generation antihistamines such as loratadine (Claritin) are
prescribed for seasonal allergies because they are: 1. More effective
than first-generation antihistamines 2. Less sedating than the first-
generation antihistamines 3.Prescription products, therefore are
covered by insurance 4. Able to be taken with central nervous system
(CNS) sedatives, such as alcohol
2. Less sedating than the first-generation antihistamines
When recommending dimenhydrinate (Dramamine) to treat motion
sickness, patients should be instructed to: 1. Take the
dimenhydrinate after they get nauseated 2.Drink lots of water while
,taking the dimenhydrinate 3. Take the dimenhydrinate 15 minutes
before it is needed 4.Double the dose if one tablet is not effective
3. Take the dimenhydrinate 15 minutes before it is needed
Decongestants such as pseudoephedrine (Sudafed): 1. Are Schedule
III drugs in all states 2. Should not be prescribed or recommended for
children under 4 years of age 3. Are effective in treating the
congestion children experience with the common cold 4. May cause
drowsiness in patients of all ages
2. Should not be prescribed or recommended for children under 4 years of
age
Cough and cold medications that contain a sympathomimetic
decongestant such as phenylephrine should be used cautiously in
what population: 1.Older adults 2.Hypertensive patients 3. Infants
4.All of the above
4.All of the above
Martin is a 60-year-old patient with hypertension. The first-line
decongestant to prescribe would be: 1. Oral pseudoephedrine 2.Oral
phenylephrine 3. Nasal oxymetazoline
4. Nasal azelastine
3. Nasal oxymetazoline
The first-line treatment for cough related to an upper respiratory tract
infection (URI) in a 5-year-old child is: 1. Fluids and symptomatic care
2. Dextromethorphan and guaifenesin syrup (Robitussin DM for Kids)
3.Guaifenesin and codeine syrup (Tussin AC) 4. Chlorpheniramine
and dextromethorphan syrup (Nyquil for Kids)
1. Fluids and symptomatic care
Prior to developing a plan for the treatment of asthma, the patient's
asthma should be classified according to the NHLBI Expert Panel 3
guidelines. In adults mild-persistent asthma is classified as asthma
symptoms that occur:
1. Daily 2.Daily and limit physical activity 3. Less than twice a week
4.More than twice a week and less than once a day
.More than twice a week and less than once a day
In children age 5 to 11 years mild-persistent asthma is diagnosed
when asthma symptoms occur: 1. At nighttime one to two times a
month 2.At nighttime three to four times a month 3. Less than twice a
week 4.Daily
, At nighttime three to four times a month
One goal of asthma therapy outlined by the NHLBI Expert Panel 3
guidelines is: 1. Ability to use albuterol daily to control symptoms
2.Minimize exacerbations to once a month 3. Keep nighttime
symptoms at a maximum of twice a week 4.Require infrequent use of
beta 2 agonists (albuterol) for relief of symptoms
4.Require infrequent use of beta 2 agonists (albuterol) for relief of
symptoms
A stepwise approach to the pharmacologic management of asthma: 1.
Begins with determining the severity of asthma and assessing asthma
control 2.Is used when asthma is severe and requires daily steroids 3.
Allows for each provider to determine their personal approach to the
care of asthmatic patients 4.Provides a framework for the
management of severe asthmatics, but is not as helpful when patients
have intermittent asthma
1. Begins with determining the severity of asthma and assessing asthma
control
Treatment for mild intermittent asthma is: 1.Daily inhaled medium-
dose corticosteroids 2. Short-acting beta-2-agonists (albuterol) as
needed 3.Long-acting beta-2-agonists every morning as a
preventative 4.Montelukast (Singulair) daily
2. Short-acting beta-2-agonists (albuterol) as needed
The first-line therapy for mild-persistent asthma is: 1.High-dose
montelukast 2.Theophylline 3. Low-dose inhaled corticosteroids
4.Long-acting beta-2-agonists
3. Low-dose inhaled corticosteroids
Monitoring a patient with persistent asthma includes: 1. Monitoring
how frequently the patient has an upper respiratory infection (URI)
during treatment
2. Monthly in-office spirometry testing 3. Determining if the patient
has increased use of his or her long-acting beta-2-agonist due to
exacerbations 4. Evaluating the patient every 1 to 6 months to
determine if the patient needs to step up or down in their therapy
Evaluating the patient every 1 to 6 months to determine if the patient needs
to step up or down in their therapy
Asthma exacerbations at home are managed by the patient by:
1.Increasing frequency of beta-2-agonists and contacting their
and Answers Latest Versions
2025 Graded A+.
Tiotropium bromide (Spiriva) is an inhaled anticholinergic: 1.Used for
the treatment of chronic obstructive pulmonary disease (COPD)
2.Used in the treatment of asthma 3. Combined with albuterol for
treatment of asthma exacerbations 4.Combined with fluticasone for
the treatment of persistent asthma
1.Used for the treatment of chronic obstructive pulmonary disease (COPD)
Christy has exercise-induced and mild persistent asthma and is
prescribed two puffs of albuterol 15 minutes before exercise and as
needed for wheezing. One puff per day of beclomethasone (QVAR) is
also prescribed. Teaching regarding her inhalers includes: 1. Use one
to two puffs of albuterol per day to prevent an attack with no more
than eight puffs per day 2. Beclomethasone needs to be used every
day to treat her asthma 3. Report any systemic side effects she is
experiencing, such as weight gain 4. Use the albuterol metered-dose
inhaler (MDI) immediately after her corticosteroid MDI to facilitate
bronchodilation
2. Beclomethasone needs to be used every day to treat her asthma
When prescribing montelukast (Singulair) for asthma, patients or
parents of patients should be instructed: 1.Montelukast twice a day is
started when there is an asthma exacerbation. 2.Patients may
experience weight gain on montelukast. 3.Aggression, anxiety,
depression, and/or suicidal thoughts may occur when taking
montelukast. 4.Lethargy and hypersomnia may occur when taking
montelukast.
3.Aggression, anxiety, depression, and/or suicidal thoughts may occur
when taking montelukast.
Montelukast (Singulair) may be prescribed for: 1. A 6-year-old child
with exercise-induced asthma 2. A 2-year-old child with moderate
,persistent asthma 3. An 18-month-old child with seasonal allergic
rhinitis 4. None of the above; montelukast is not approved for use in
children
2. A 2-year-old child with moderate persistent asthma
The known drug interactions with the inhaled corticosteroid
beclomethasone (QVAR) include: 1.Albuterol 2. MMR vaccine 3.Insulin
4. None of the above
4. None of the above
When educating patients who are starting on inhaled corticosteroids,
the provider should tell them that: 1. They need to get any live
vaccines before starting the medication. 2. Inhaled corticosteroids
need to be used daily during asthma exacerbations to be effective.
3. Patients should rinse their mouths out after using the inhaled
corticosteroid to prevent thrush. 4. They can triple the dose number
of inhalations of medication during colds to prevent needing systemic
steroids.
3. Patients should rinse their mouths out after using the inhaled
corticosteroid to prevent thrush.
Patients with allergic rhinitis may benefit from a prescription of: 1.
Fluticasone (Flonase) 2.Cetirizine (Zyrtec) 3. OTC cromolyn nasal
spray (Nasalcrom) 4.Any of the above
4.Any of the above
Howard is a 72-year-old male who occasionally takes
diphenhydramine for his seasonal allergies. Monitoring for this
patient taking diphenhydramine would include assessing for:
1.Urinary retention 2. Cardiac output 3. Peripheral edema 4.Skin rash
1.Urinary retention
First-generation antihistamines such as loratadine (Claritin) are
prescribed for seasonal allergies because they are: 1. More effective
than first-generation antihistamines 2. Less sedating than the first-
generation antihistamines 3.Prescription products, therefore are
covered by insurance 4. Able to be taken with central nervous system
(CNS) sedatives, such as alcohol
2. Less sedating than the first-generation antihistamines
When recommending dimenhydrinate (Dramamine) to treat motion
sickness, patients should be instructed to: 1. Take the
dimenhydrinate after they get nauseated 2.Drink lots of water while
,taking the dimenhydrinate 3. Take the dimenhydrinate 15 minutes
before it is needed 4.Double the dose if one tablet is not effective
3. Take the dimenhydrinate 15 minutes before it is needed
Decongestants such as pseudoephedrine (Sudafed): 1. Are Schedule
III drugs in all states 2. Should not be prescribed or recommended for
children under 4 years of age 3. Are effective in treating the
congestion children experience with the common cold 4. May cause
drowsiness in patients of all ages
2. Should not be prescribed or recommended for children under 4 years of
age
Cough and cold medications that contain a sympathomimetic
decongestant such as phenylephrine should be used cautiously in
what population: 1.Older adults 2.Hypertensive patients 3. Infants
4.All of the above
4.All of the above
Martin is a 60-year-old patient with hypertension. The first-line
decongestant to prescribe would be: 1. Oral pseudoephedrine 2.Oral
phenylephrine 3. Nasal oxymetazoline
4. Nasal azelastine
3. Nasal oxymetazoline
The first-line treatment for cough related to an upper respiratory tract
infection (URI) in a 5-year-old child is: 1. Fluids and symptomatic care
2. Dextromethorphan and guaifenesin syrup (Robitussin DM for Kids)
3.Guaifenesin and codeine syrup (Tussin AC) 4. Chlorpheniramine
and dextromethorphan syrup (Nyquil for Kids)
1. Fluids and symptomatic care
Prior to developing a plan for the treatment of asthma, the patient's
asthma should be classified according to the NHLBI Expert Panel 3
guidelines. In adults mild-persistent asthma is classified as asthma
symptoms that occur:
1. Daily 2.Daily and limit physical activity 3. Less than twice a week
4.More than twice a week and less than once a day
.More than twice a week and less than once a day
In children age 5 to 11 years mild-persistent asthma is diagnosed
when asthma symptoms occur: 1. At nighttime one to two times a
month 2.At nighttime three to four times a month 3. Less than twice a
week 4.Daily
, At nighttime three to four times a month
One goal of asthma therapy outlined by the NHLBI Expert Panel 3
guidelines is: 1. Ability to use albuterol daily to control symptoms
2.Minimize exacerbations to once a month 3. Keep nighttime
symptoms at a maximum of twice a week 4.Require infrequent use of
beta 2 agonists (albuterol) for relief of symptoms
4.Require infrequent use of beta 2 agonists (albuterol) for relief of
symptoms
A stepwise approach to the pharmacologic management of asthma: 1.
Begins with determining the severity of asthma and assessing asthma
control 2.Is used when asthma is severe and requires daily steroids 3.
Allows for each provider to determine their personal approach to the
care of asthmatic patients 4.Provides a framework for the
management of severe asthmatics, but is not as helpful when patients
have intermittent asthma
1. Begins with determining the severity of asthma and assessing asthma
control
Treatment for mild intermittent asthma is: 1.Daily inhaled medium-
dose corticosteroids 2. Short-acting beta-2-agonists (albuterol) as
needed 3.Long-acting beta-2-agonists every morning as a
preventative 4.Montelukast (Singulair) daily
2. Short-acting beta-2-agonists (albuterol) as needed
The first-line therapy for mild-persistent asthma is: 1.High-dose
montelukast 2.Theophylline 3. Low-dose inhaled corticosteroids
4.Long-acting beta-2-agonists
3. Low-dose inhaled corticosteroids
Monitoring a patient with persistent asthma includes: 1. Monitoring
how frequently the patient has an upper respiratory infection (URI)
during treatment
2. Monthly in-office spirometry testing 3. Determining if the patient
has increased use of his or her long-acting beta-2-agonist due to
exacerbations 4. Evaluating the patient every 1 to 6 months to
determine if the patient needs to step up or down in their therapy
Evaluating the patient every 1 to 6 months to determine if the patient needs
to step up or down in their therapy
Asthma exacerbations at home are managed by the patient by:
1.Increasing frequency of beta-2-agonists and contacting their
